ArticleFrontiers in medicine2026
Serum EV-enriched proteomics reveals host-response subtypes and molecular similarity to organ dysfunction phenotypes in sepsis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sepsis is a heterogeneous syndrome characterized by dysregulated host responses and diverse patterns of organ dysfunction. This study aimed to characterize serum extracellular vesicle (EV)-enriched proteomic heterogeneity in sepsis and assess whether proteomic subtypes identified among Sepsis-only patients showed molecular similarity to established organ dysfunction phenotypes. Methods: In this single-center observational study, serum EV-enriched preparations were analyzed from 250 patients with sepsis and 50 healthy controls enrolled between June 2021 and December 2022. ARDS and AKI status was determined at blood sampling, and patients with neither condition were classified as Sepsis-only. After proteomic quality control, 231 patients and 48 controls were included. Non-negative matrix factorization was used to identify proteomic subtypes among Sepsis-only patients. Centroid projection and clinically adjusted sensitivity analyses evaluated cross-sectional molecular similarity between these subtypes and established S-AKI, S-ARDS, and S-ARDS&AKI phenotypes. An exploratory elastic-net protein panel was derived, and the downstream supervised workflow was evaluated using repeated nested cross-validation conditional on the original subtype labels. Results: A total of 4,754 protein groups were quantified across 279 samples. Three proteomic subtypes were identified among 96 Sepsis-only patients. S1 showed less pronounced inflammatory features, whereas S2 was characterized by cellular immune and metabolic-stress pathways and S3 by humoral immune, complement/coagulation, hemostatic, and acute-phase processes. These molecular patterns were not fully captured by conventional severity scores. The organ dysfunction groups showed partial and reference-dependent molecular similarity to S3 after clinical adjustment. A hypothesis-generating 15-protein panel captured features shared by S3 and established organ dysfunction relative to S2. Conclusions: Serum EV-enriched proteomics revealed distinct host-response subtypes within the Sepsis-only group and contemporaneous molecular features shared with established organ dysfunction. These findings advance the molecular characterization of sepsis heterogeneity and provide a focused framework for future longitudinal and external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.